For decades, treatment of infectious diseases has been a strong focus of interest, for both researchers and healthcare providers. Chronic infection with Helicobacter pylori (H. pylori) has been reported to be associated with several diseases, such as ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. Infection with H. pylori is generally acquired during childhood and can persist indefinitely, if not treated systematically. Unfortunately, although several strategies have shown high efficacy results, treatment of the H. pylori infection fails in about 25%-30% of infected children. One main reason for this is due to the extensive use of antibiotics, which has created antibiotic resistance, associated with other adverse effects as well. Therefore, it is crucial to find alternative strategies to combat this resistance, and increase treatment efficacy results. Probiotics, which are live microorganisms that are orally administrated, have been found to be a useful regimen in the treatment of the H. pylori infection in children. Their use as a dietary supplement alone, or in combination with antibiotics, resulted in reduced side effects and higher efficacy rates of the H. pylori infection in children. Some probiotics can be considered an adjunctive treatment, especially when eradication of the H. pylori infection fails during initial treatment, and to help reduce adverse effects. However, the evidence of the beneficial role of probiotics is limited due to the small number of clinical trials that have been conducted and heterogeneity across studies in strains and dosage. Additionally, no investigations have been carried out in asymptomatic children. Therefore, large well-conducted studies are needed to evaluate the efficacy and safety of probiotics as an adjuvant therapy of the H. pylori infection.

Department of Natural Drugs Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Palackého tř 1946 1 612 42 Brno Czech Republic

Museum of the Brno Region Museum of Literature in Moravia Porta Coeli 1001 66602 Předklášteří Czech Republic

See more in PubMed

Hassan S.T.S., Berchová K., Majerová M., Pokorná M., Švajdlenka E. In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. Pharm. Biol. 2016;54:1736–1740. doi: 10.3109/13880209.2015.1126618. PubMed DOI

Go M. Natural history and epidemiology of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2002;16:S3–S15. doi: 10.1046/j.1365-2036.2002.0160s1003.x. PubMed DOI

Goodwin C.S., Mendall M.M., Northfield T.C. Helicobacter pylori infection. Lancet. 1997;349:265–269. doi: 10.1016/S0140-6736(96)07023-7. PubMed DOI

Hassan S.T.S., Žemlička M. Plant-Derived Urease Inhibitors as Alternative Chemotherapeutic Agents. Arch. Pharm. (Weinh.) 2016;349:507–522. doi: 10.1002/ardp.201500019. PubMed DOI

Homan M., Šterbenc A., Kocjan B.J., Luzar B., Zidar N., Orel R., Poljak M. Prevalence of the Helicobacter pylori babA2 gene and correlation with the degree of gastritis in infected Slovenian children. Antonie Van Leeuwenhoek. 2014;106:637–645. doi: 10.1007/s10482-014-0234-0. PubMed DOI

Homan M., Luzar B., Kocjan B.J., Orel R., Mocilnik T., Shrestha M., Kveder M., Poljak M. Prevalence and clinical relevance of cagA, vacA, and iceA genotypes of Helicobacter pylori isolated from Slovenian children. J. Pediatr. Gastroenterol. Nutr. 2009;49:289–296. doi: 10.1097/MPG.0b013e31818f09f2. PubMed DOI

Malfertheiner P., Megraud F., O’Morain C.A., Atherton J., Axon A.T.R., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T., et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646–664. doi: 10.1136/gutjnl-2012-302084. PubMed DOI

Kawakami E., Machado R.S., Ogata S.K., Langner M. Decrease in prevalence of Helicobacter pylori infection during a 10-year period in Brazilian children. Arq. Gastroenterol. 2008;45:147–151. doi: 10.1590/S0004-28032008000200011. PubMed DOI

Elitsur Y., Dementieva Y., Rewalt M., Lawrence Z. Helicobacter pylori infection rate decreases in symptomatic children: A retrospective analysis of 13 years (1993–2005) from a gastroenterology clinic in West Virginia. J. Clin. Gastroenterol. 2009;43:147–151. doi: 10.1097/MCG.0b013e318157e4e7. PubMed DOI

Sullivan A., Nord C.E. Probiotics and gastrointestinal diseases. J. Intern. Med. 2005;257:78–92. doi: 10.1111/j.1365-2796.2004.01410.x. PubMed DOI

Saxelin M., Tynkkynen S., Mattila-Sandholm T., de Vos W.M. Probiotic and other functional microbes: From markets to mechanisms. Curr. Opin. Biotechnol. 2005;16:204–211. doi: 10.1016/j.copbio.2005.02.003. PubMed DOI

Gill H.S., Guarner F. Probiotics and human health: A clinical perspective. Postgrad. Med. J. 2004;80:516–526. doi: 10.1136/pgmj.2003.008664. PubMed DOI PMC

Aiba Y., Suzuki N., Kabir A.M., Takagi A., Koga Y. Lactic acid mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am. J. Gastroenterol. 1998;93:2097–2101. doi: 10.1111/j.1572-0241.1998.00600.x. PubMed DOI

Sgouras D., Maragkoudakis P., Petraki K., Martinez-Gonzalez B., Eriotou E., Michopoulos S., Kalantzopoulos G., Tsakalidou E., Mentis A. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl. Environ. Microbiol. 2004;70:518–526. doi: 10.1128/AEM.70.1.518-526.2004. PubMed DOI PMC

Cindoruk M., Erkan G., Karakan T., Dursun A., Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: A prospective randomized placebo controlled double-blind study. Helicobacter. 2007;12:309–316. doi: 10.1111/j.1523-5378.2007.00516.x. PubMed DOI

Gotteland M., Cruchet S. Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers. J. Antimicrob. Chemother. 2003;51:1317–1319. doi: 10.1093/jac/dkg227. PubMed DOI

Miki K., Urita Y., Ishikawa F., Iino T., Shibahara-Sone H., Akahoshi R., Mizusawa S., Nose A., Nozaki D., Hirano K., et al. Effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori and serum pepsinogen levels in humans. J. Dairy Sci. 2007;90:2630–2640. doi: 10.3168/jds.2006-803. PubMed DOI

Sakamoto I., Igarashi M., Kimura K., Takagi A., Miwa T., Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J. Antimicrob. Chemother. 2001;47:709–710. doi: 10.1093/jac/47.5.709. PubMed DOI

Sykora J., Valecková K., Amlerová J., Siala K., Decek P., Watkins S. Effects of a specially designed fermented milk product containing probiotic Lactobacilli casei DN-114 001 and the eradication of H. pylori in children. J. Clin. Gastroenterol. 2005;39:692–698. doi: 10.1097/01.mcg.0000173855.77191.44. PubMed DOI

Lionetti E., Miniello V.L., Castellaneta S.P., Magista A.M., de Canio A., Maurogiovanni G., Ierardi E., Cavallo L., Francavilla R. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: A randomized placebo controlled trial. Aliment. Pharmacol. Ther. 2006;24:1461–1468. doi: 10.1111/j.1365-2036.2006.03145.x. PubMed DOI

Goldman C.G., Barrado D.A., Balcarce N., Rua E.C., Oshiro M., Calcagno M.L., Janjetic M., Fuda J., Weill R., Salgueiro M.J., et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition. 2006;10:984–988. doi: 10.1016/j.nut.2006.06.008. PubMed DOI

Szajewska A., Horvath A., Piwowarczyk A. Meta-analysis: The effects of Saccharomyces boulardii supplementation on Helicobacter pilori eradication rates and side effects during treatment. Aliment. Pharmacol. Ther. 2010;32:1069–1079. doi: 10.1111/j.1365-2036.2010.04457.x. PubMed DOI

Li S., Hang X.L., Sui J.Z., Chen S.Y., Xie Y.T., Deng Y., Wang J., Xie L., Li T.J., He Y., et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur. J. Pediatr. 2014;173:153–161. doi: 10.1007/s00431-013-2220-3. PubMed DOI

Bin Z., Ya-Zheng X., Zhao-Hui D., Bo C., Li-Rong J., Vandenplas Y. The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in children. Pediatr. Gastroenterol. Hepatol. Nutr. 2015;18:17–22. doi: 10.5223/pghn.2015.18.1.17. PubMed DOI PMC

Videlock E.J., Cremonini F. Meta-analysis: Probiotics in antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther. 2012;35:1355–1369. doi: 10.1111/j.1365-2036.2012.05104.x. PubMed DOI